S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.68 (+1.52%)
AAPL   179.49 (-0.70%)
MSFT   415.56 (+0.46%)
META   502.51 (+2.53%)
GOOGL   137.35 (-0.80%)
AMZN   178.56 (+1.02%)
TSLA   202.93 (+0.52%)
NVDA   819.40 (+3.57%)
NIO   5.79 (+0.70%)
AMD   201.28 (+4.54%)
BABA   74.66 (+0.85%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.14 (+5.00%)
CGC   3.20 (-2.74%)
GE   158.57 (+1.07%)
DIS   112.04 (+0.41%)
AMC   4.34 (+0.46%)
PFE   26.58 (+0.08%)
PYPL   60.57 (+0.38%)
XOM   105.88 (+1.30%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.68 (+1.52%)
AAPL   179.49 (-0.70%)
MSFT   415.56 (+0.46%)
META   502.51 (+2.53%)
GOOGL   137.35 (-0.80%)
AMZN   178.56 (+1.02%)
TSLA   202.93 (+0.52%)
NVDA   819.40 (+3.57%)
NIO   5.79 (+0.70%)
AMD   201.28 (+4.54%)
BABA   74.66 (+0.85%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.14 (+5.00%)
CGC   3.20 (-2.74%)
GE   158.57 (+1.07%)
DIS   112.04 (+0.41%)
AMC   4.34 (+0.46%)
PFE   26.58 (+0.08%)
PYPL   60.57 (+0.38%)
XOM   105.88 (+1.30%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.68 (+1.52%)
AAPL   179.49 (-0.70%)
MSFT   415.56 (+0.46%)
META   502.51 (+2.53%)
GOOGL   137.35 (-0.80%)
AMZN   178.56 (+1.02%)
TSLA   202.93 (+0.52%)
NVDA   819.40 (+3.57%)
NIO   5.79 (+0.70%)
AMD   201.28 (+4.54%)
BABA   74.66 (+0.85%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.14 (+5.00%)
CGC   3.20 (-2.74%)
GE   158.57 (+1.07%)
DIS   112.04 (+0.41%)
AMC   4.34 (+0.46%)
PFE   26.58 (+0.08%)
PYPL   60.57 (+0.38%)
XOM   105.88 (+1.30%)
S&P 500   5,137.18 (+0.80%)
DOW   39,092.88 (+0.25%)
QQQ   445.68 (+1.52%)
AAPL   179.49 (-0.70%)
MSFT   415.56 (+0.46%)
META   502.51 (+2.53%)
GOOGL   137.35 (-0.80%)
AMZN   178.56 (+1.02%)
TSLA   202.93 (+0.52%)
NVDA   819.40 (+3.57%)
NIO   5.79 (+0.70%)
AMD   201.28 (+4.54%)
BABA   74.66 (+0.85%)
T   17.02 (+0.53%)
F   12.41 (-0.24%)
MU   95.14 (+5.00%)
CGC   3.20 (-2.74%)
GE   158.57 (+1.07%)
DIS   112.04 (+0.41%)
AMC   4.34 (+0.46%)
PFE   26.58 (+0.08%)
PYPL   60.57 (+0.38%)
XOM   105.88 (+1.30%)
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

$2.70
+0.37 (+15.88%)
(As of 02/29/2024 ET)
Today's Range
$2.49
$2.70
50-Day Range
$1.80
$8.25
52-Week Range
$0.39
$18.00
Volume
1,196 shs
Average Volume
5,126 shs
Market Capitalization
$8.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARTH stock logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Stock Price History

ARTH Stock News Headlines

Arch Therapeutics Inc ARTH
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics Provides AC5® Commercialization Update
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Dr. Arth Patel
Double Arch
Arch Therapeutics Inc (ARTHD)
ARTH Arch Therapeutics, Inc.
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/01/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-6,980,000.00
Net Margins
-6,809.45%
Pretax Margin
-6,808.58%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($3.09) per share

Miscellaneous

Free Float
2,955,000
Market Cap
$8.34 million
Optionable
Not Optionable
Beta
3.63
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 59)
    Co-Founder, Chairman, President & CEO
    Comp: $450.5k
  • Mr. Michael S. Abrams (Age 54)
    CFO & Treasurer
    Comp: $325k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Shawn Carlson
    Vice President of Sales














ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed in 2024?

Arch Therapeutics' stock was trading at $7.24 at the beginning of 2024. Since then, ARTH stock has decreased by 62.7% and is now trading at $2.70.
View the best growth stocks for 2024 here
.

Are investors shorting Arch Therapeutics?

Arch Therapeutics saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 12,600 shares, a decrease of 41.4% from the January 31st total of 21,500 shares. Based on an average daily trading volume, of 8,600 shares, the short-interest ratio is presently 1.5 days.
View Arch Therapeutics' Short Interest
.

When is Arch Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ARTH earnings forecast
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its earnings results on Tuesday, February, 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. The biotechnology company earned $0.05 million during the quarter.

What other stocks do shareholders of Arch Therapeutics own?
How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ARTH) was last updated on 3/1/2024 by MarketBeat.com Staff